RBC Capital analyst Luca Issi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $82 and keeps an Outperform rating on the shares. The company is poised to successfully transition to a fully integrated commercial organization as its Tryngolza is off to a good start in FCS, and the firm believes that recent data in sHTG will open up a much broader opportunity given a total addressable market of 1M patients in the US alone, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Arrowhead price target raised to $100 from $70 at Piper Sandler
- Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
- Ionis Pharmaceuticals price target raised to $97 from $86 at BofA
- Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships
- Ionis Pharmaceuticals gets Breakthrough Therapy designation for zilganersen